Pfizer Interest In Biosimilars Appears To Decline As Firm Ceases To Split Out Segment

Launch Of Humira Challenger In 2023 May Rejuvenate The Area

08 Nov 2022

Pfizer appears to be maintaining its “opportunistic” approach to biosimilars, having ceased to split out the business unit’s results during its Q3 earnings report.

Pfizer's biosimilar business appears to be on the backburner for the time being • Source: Shutterstock

Pfizer’s interest in its biosimilars business appears to be on the decline. The firm will no longer split out quarterly results for the segment from its Q3 earnings release report onward, and made little mention of the unit during its results call.

“The reason biosimilars are not included as a separate line in the charts is due to the change in company...